UGC Aparato Digestivo and Servicio de Farmacología Clínica, Instituto de Investigación Biomédica de Málaga-IBIMA, Hospital Universitario Virgen de la Victoria, Universidad de Málaga, Málaga, Spain; Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Madrid, Spain.
UGC Aparato Digestivo and Servicio de Farmacología Clínica, Instituto de Investigación Biomédica de Málaga-IBIMA, Hospital Universitario Virgen de la Victoria, Universidad de Málaga, Málaga, Spain.
J Hepatol. 2021 Jul;75(1):86-97. doi: 10.1016/j.jhep.2021.01.029. Epub 2021 Feb 1.
BACKGROUND & AIMS: Prospective drug-induced liver injury (DILI) registries are important sources of information on idiosyncratic DILI. We aimed to present a comprehensive analysis of 843 patients with DILI enrolled into the Spanish DILI Registry over a 20-year time period.
Cases were identified, diagnosed and followed prospectively. Clinical features, drug information and outcome data were collected.
A total of 843 patients, with a mean age of 54 years (48% females), were enrolled up to 2018. Hepatocellular injury was associated with younger age (adjusted odds ratio [aOR] per year 0.983; 95% CI 0.974-0.991) and lower platelet count (aOR per unit 0.996; 95% CI 0.994-0.998). Anti-infectives were the most common causative drug class (40%). Liver-related mortality was more frequent in patients with hepatocellular damage aged ≥65 years (p = 0.0083) and in patients with underlying liver disease (p = 0.0221). Independent predictors of liver-related death/transplantation included nR-based hepatocellular injury, female sex, higher onset aspartate aminotransferase (AST) and bilirubin values. nR-based hepatocellular injury was not associated with 6-month overall mortality, for which comorbidity burden played a more important role. The prognostic capacity of Hy's law varied between causative agents. Empirical therapy (corticosteroids, ursodeoxycholic acid and MARS) was prescribed to 20% of patients. Drug-induced autoimmune hepatitis patients (26 cases) were mainly females (62%) with hepatocellular damage (92%), who more frequently received immunosuppressive therapy (58%).
AST elevation at onset is a strong predictor of poor outcome and should be routinely assessed in DILI evaluation. Mortality is higher in older patients with hepatocellular damage and patients with underlying hepatic conditions. The Spanish DILI Registry is a valuable tool in the identification of causative drugs, clinical signatures and prognostic risk factors in DILI and can aid physicians in DILI characterisation and management.
Clinical information on drug-induced liver injury (DILI) collected from enrolled patients in the Spanish DILI Registry can guide physicians in the decision-making process. We have found that older patients with hepatocellular type liver injury and patients with additional liver conditions are at a higher risk of mortality. The type of liver injury, patient sex and analytical values of aspartate aminotransferase and total bilirubin can also help predict clinical outcomes.
前瞻性药物性肝损伤(DILI)登记处是研究特发性 DILI 的重要信息来源。我们旨在对西班牙 DILI 登记处 20 年来登记的 843 例 DILI 患者进行全面分析。
前瞻性识别、诊断和随访病例。收集临床特征、药物信息和结局数据。
共纳入 843 例患者,平均年龄 54 岁(48%为女性),截至 2018 年。肝细胞损伤与年龄较小有关(每年调整优势比 [aOR] 0.983;95%CI 0.974-0.991)和血小板计数较低(每单位 aOR 0.996;95%CI 0.994-0.998)。抗感染药物是最常见的致病药物类别(40%)。年龄≥65 岁的肝细胞损伤患者(p=0.0083)和存在基础肝病的患者(p=0.0221)更易发生与肝相关的死亡率/肝移植。与肝相关死亡/肝移植相关的独立预测因素包括基于 nR 的肝细胞损伤、女性、较高的天门冬氨酸氨基转移酶(AST)和胆红素起始值。基于 nR 的肝细胞损伤与 6 个月总死亡率无关,而合并症负担在其中发挥更重要的作用。Hy's 法则的预后能力在不同的致病药物之间存在差异。经验性治疗(皮质类固醇、熊去氧胆酸和 MARS)应用于 20%的患者。药物性自身免疫性肝炎患者(26 例)主要为女性(62%),表现为肝细胞损伤(92%),更常接受免疫抑制治疗(58%)。
发病时的 AST 升高是预后不良的强烈预测因子,应在 DILI 评估中常规评估。年龄较大的肝细胞损伤患者和存在基础肝疾病的患者死亡率更高。西班牙 DILI 登记处是识别 DILI 中致病药物、临床特征和预后危险因素的有价值工具,并可帮助医生对 DILI 进行特征描述和管理。
非专业人士请不要自行翻译,仅供参考。